Ionis Pharma

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ionis Pharma excels in Q4, eyes revenue growth and strategic expansion

Ionis Pharma's Q4 2022 performance reflects strong revenue growth, pipeline advancements, and strategic positioning for future success.
The company's focus on commercialization, R&D innovation, and financial discipline underscores its resilience and growth potential in the biopharmaceutical industry.
While facing challenges in operational costs and market dynamics, Ionis Pharma remains well-positioned to leverage opportunities in genetic medicines and revenue diversification.

Ionis Pharma reports strong Q1 earnings and outlines growth plans

Ionis Pharma's Q1 performance solid with revenue growth and strong cash position
Company's strengths lie in FDA approvals, positive study data, and pipeline progress
Challenges include rising expenses, competitive landscape, and pricing strategies
Opportunities seen in PV market, HAE program, and growth prospects in coming years

Ionis Pharma reports strong Q2 performance and prepares for launches

Ionis Pharma's Q2 2023 earnings call highlighted strong performance, with revenue growth, key milestones in pipeline advancements, and a solid financial position.
The company faces challenges in study readout timing, competitive landscape changes, and market competition but has opportunities for growth through successful enrollment and product launches.
Key strengths include successful collaborations, encouraging interim results for SPINRAZA, and preparations for upcoming product launches, positioning Ionis Pharma for future success.
Overall, Ionis Pharma remains focused on advancing its pipeline, meeting financial guidance, and leveraging opportunities for growth in the biopharmaceutical market.

Ionis Pharma reports strong Q3 performance and neurology pipeline advancements

Ionis Pharma's Q3 earnings call highlighted strong performance, strategic successes, and advancements in the neurology pipeline.
The company faces challenges in a competitive landscape but has strengths in partnerships, innovation, and pricing strategies.
Opportunities lie in upcoming data releases, potential treatment benefits, and market differentiation strategies.
Overall, Ionis Pharma remains focused on delivering value to patients and investors through its innovative therapeutics.

Ionis Pharma reports robust 2023 results and eyes growth opportunities

Ionis Pharma's strong financial performance in 2023 and projected revenue for 2024 reflect a promising outlook for the company's growth and commercialization efforts.
While facing challenges in patient eligibility and treatment optimization, Ionis Pharma's focus on pipeline advancement and strategic investments positions it well for future success.
The company's emphasis on neurological disease platforms, upcoming data readouts, and collaborations present significant opportunities for expansion and innovation.

Ionis Pharma reports robust Q1 performance and advances key treatments

Ionis Pharma's Q1 2024 performance reflects strong revenue growth and progress in key pipeline programs, positioning the company for future success and sustained positive cash flow.
With a focus on strategic investments, innovative treatments, and upcoming data presentations, Ionis demonstrates a commitment to driving growth and addressing unmet medical needs.
While facing challenges in managing expenses and securing regulatory approvals, Ionis Pharma remains well-positioned to capitalize on market opportunities and partnerships for continued development and commercial success.

Ionis Pharma reports solid Q2 earnings, eyes growth through innovation

Ionis Pharma's Q2 performance reflects steady revenue growth and positive feedback on recent launches and ongoing trials.
The company's strengths lie in its innovative therapies, strong clinical profile, and strategic focus on expanding the product portfolio.
Challenges include sustaining momentum in competitive markets and ensuring successful commercialization of upcoming products.
Opportunities exist in market expansion, new patient segments, partnerships for pipeline growth, and investments in next-gen technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

CARLSBAD, Calif., April 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a rare and generally fatal neurological disorder.

Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease

We believe that Ionis Pharmaceuticals stock, a biotech company that specializes in discovering and developing RNA-targeted therapeutics, is a good buying opportunity at the present time. IONS stock trades near $41 currently and it is, in fact, down 34% from its pre-Covid high of around $62.

Can Ionis Pharmaceuticals Stock See A Rebound After Falling 28% YTD?

Ionis Pharmaceuticals Inc (NASDAQ: IONS) said it expanded its distribution agreement with Swedish Orphan Biovitrum AB (“Sobi”) for Tegsedi in North America. Tegsedi is indicated for polyneuropathy (a condition where multiple peripheral nerves become damaged) in adults with hereditary transthyretin amyloidosis.

Ionis Axes Akcea's 70% Workforce Under Restructuring Plan

NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

CARLSBAD, Calif., April 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in patients with amyotrophic lateral sclerosis (ALS) with mutations in the fused in sarcoma gene (FUS).

Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS

Ionis Pharmaceuticals is at a crossroads. The pipeline begins to take form with a recent setback creating a waterfall dive in the share price.

Ionis Pharmaceuticals: Recent Setback Offers An Interesting Opportunity

Ionis Pharmaceuticals Inc (NASDAQ: IONS) has announced data from a Phase 2 study evaluating IONIS-PKK-LRx in patients with hereditary angioedema (HAE). The study met its primary and secondary endpoints, achieving significant reductions in the number of attacks suffered by HAE patients compared to placebo.

Ionis Pharma's Ligand-Conjugated Antisense Hits Primary Endpoint Goal In Hereditary Angioedema Study

CARLSBAD, Calif., March 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that data from a Phase 2 clinical study of IONIS-PKK-LRx met its primary and secondary endpoints, achieving significant reductions in the number of attacks suffered by patients with hereditary angioedema (HAE) compared to placebo.

Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Ionis Pharmaceuticals (IONS) Down 20.4% Since Last Earnings Report: Can It Rebound?

3D Systems

Raven Industries

Cathie Wood's Ark Invest continues to add more shares to its holdings with it picking out a few companies worth noting on Wednesday. The post DDD, AONE, RAVN, ION: 4 Stocks That Cathie Wood's ARK Funds Are Betting On Today appeared first on InvestorPlace.

DDD, AONE, RAVN, ION: 4 Stocks That Cathie Wood's ARK Funds Are Betting On Today

The biotech's partner is stopping a late-stage clinical trial for a Huntington's disease treatment.

Here's Why Ionis Pharmaceuticals Stock Got Slammed Today

Roche Holding AG

Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.

Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails

Shares of Ionis Pharmaceuticals Inc. were down 19.6% in premarket trading on Tuesday, the day after the company said Roche Holding AG decided to discontinue a late-stage clinical trial for a Huntington's disease treatment candidate. Roche licensed the investigational therapy, tominersen, from Ionis in December 2017.

Ionis shares tumble19% after Roche halts Phase 3 study for rare-disease drug

Roche Holdings AG (OTCMKTS: RHHBY) has halted dosing for its Phase 3 study of tominersen, an antisense drug targeting the huntingtin protein and a mutant variant. Roche is calling off the study after an independent data committee “made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants.

Ionis Pharma Stock Is Trading Lower After Roche Drops Huntington's Disease Trial With Tominersen

Deere & Company

Every night, Cathie Wood's Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause certain stocks to see a spike in the after-hours session.

Ionis, 3D Systems, Unity, BYD, Deere — What Cathie Wood's Ark Bought And Sold Today

CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD).

Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)

CARLSBAD, Calif., March 1, 2021 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based researchers whose work advances the understanding of transthyretin amyloidosis (ATTR), facilitates...

Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis

Shares of Ionis Pharmaceuticals Inc (NASDAQ: IONS) has received a price target decrease from $60 to $55 by Piper Sandler. These are the details.

IONS Stock Price: $55 Target (Down From $60) By Piper Sandler

Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.

Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2020 Results - Earnings Call Transcript

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share fell 39.10% over the past year to $0.81, which beat the estimate of $0.28.

Ionis Pharmaceuticals: Q4 Earnings Insights

CARLSBAD, Calif., Feb. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter of 2020 and recent business highlights. "Last year, we laid out a bold new vision for the Company and took important steps towards our...

Ionis reports fourth quarter and full year 2020 financial results and recent business achievements

CARLSBAD, Calif., Feb. 11, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern Time to discuss its 2020 financial results and report on pipeline and business progress. Interested...

Ionis to hold 2020 financial results webcast

Neurocrine Biosciences

Vertex, Inc.

Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in 2020, on account of clinical setbacks or due to Covid-19 related disruptions of the health care industry.

Neurocrine, Ionis, Vertex: Underperforming Healthcare Stocks Poised To Recover

CARLSBAD, Calif., Jan. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical development officer. In this role, Dr. Schneider will oversee clinical development of novel...

News for Ionis Pharma Stock (IONS)